Advances in the treatment of atherosclerosis with ligand-modified nanocarriers

Xiujiao Deng; Jinghao Wang; Shanshan Yu; Suiyi Tan; Tingting Yu; Qiaxin Xu; Nenghua Chen; Siqi Zhang; Ming-Rong Zhang; Kuan Hu; Zeyu Xiao

doi:10.1002/EXP.20230090

PDF

Exploration ›› 2024, Vol. 4 ›› Issue (3) : 20230090-24. DOI: 10.1002/EXP.20230090

REVIEW

Advances in the treatment of atherosclerosis with ligand-modified nanocarriers

Xiujiao Deng¹^,²^,³ ,
Jinghao Wang¹^,² ,
Shanshan Yu⁴ ,
Suiyi Tan³ ,
Tingting Yu¹^,² ,
Qiaxin Xu¹^,² ,
Nenghua Chen¹^,² ,
Siqi Zhang⁵ ,
Ming-Rong Zhang⁷ ,
Kuan Hu⁵^,⁷ ,
Zeyu Xiao²^,⁶

Author information +

History +

Abstract

Atherosclerosis, a chronic disease associated with metabolism, poses a significant risk to human well-being. Currently, existing treatments for atherosclerosis lack sufficient efficiency, while the utilization of surface-modified nanoparticles holds the potential to deliver highly effective therapeutic outcomes. These nanoparticles can target and bind to specific receptors that are abnormally over-expressed in atherosclerotic conditions. This paper reviews recent research (2018–present) advances in various ligand-modified nanoparticle systems targeting atherosclerosis by specifically targeting signaturemolecules in the hope of precise treatment at themolecular level andconcludes with a discussion of the challenges and prospects in this field. The intention of this review is to inspire novel concepts for the design and advancement of targeted nanomedicines tailored specifically for the treatment of atherosclerosis.

Keywords

atherosclerosis / drug delivery / ligand-modified / nano-drugs / targeted therapies

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Xiujiao Deng, Jinghao Wang, Shanshan Yu, Suiyi Tan, Tingting Yu, Qiaxin Xu, Nenghua Chen, Siqi Zhang, Ming-Rong Zhang, Kuan Hu, Zeyu Xiao. Advances in the treatment of atherosclerosis with ligand-modified nanocarriers. Exploration, 2024, 4(3): 20230090‒24 https://doi.org/10.1002/EXP.20230090